Vor Biopharma Inc.
100 Cambridgepark Drive
Suite 101
Cambridge, MA 02140
United States
617 655 6580
https://www.vorbio.com
版塊: Healthcare
行業: Biotechnology
全職員工: 168
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Robert Ang M.B.A., M.D., MBBS | President, CEO & Director | 943.91k | 無 | 1975 |
| Dr. Tirtha Chakraborty Ph.D. | Chief Scientific Officer | 661.98k | 無 | 1973 |
| Dr. Eyal C. Attar M.D. | Chief Medical Officer | 660.55k | 無 | 1971 |
| Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D. | Scientific Founder & Chairman of Scientific Advisory Board | 無 | 無 | 1971 |
| Dr. Nathan D. Jorgensen M.B.A., Ph.D. | Chief Financial Officer | 608.48k | 無 | 1977 |
| Ms. Tania Philipp | Chief People Officer | 無 | 無 | 1972 |
| Mr. John C. King M.B.A. | Chief Commercial Officer | 無 | 無 | 1976 |
| Mr. Samir Vattompadam M.S. | Senior Vice President of Portfolio Strategy & Program Management | 無 | 無 | 無 |
| Mr. David Phillips M.B.A. | Senior VP & Head of Quality | 無 | 無 | 無 |
描述
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
公司管治
截至 2024年5月1日 止，Vor Biopharma Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：6；董事會：6；股東權利：8；現金賠償：9。
